Get started
Author

Dieter H. Lang

Observed names: D Lang, D. Lang, Dieter H Lang, Dieter Lang, Lang, Dieter
Institution: Bayer (Germany)
Observed institutions: University of North Carolina at Chapel Hill, Merck & Co., Inc., Rahway, NJ, USA (United States), Biogen (United States), Amgen (United States), Pfizer (United States), Friedrich-Alexander-Universität Erlangen-Nürnberg, Genentech, GlaxoSmithKline (United Kingdom), University of Washington, Bristol-Myers Squibb (United States), EMD Serono, Inc. (United States), Novartis (United States), Eisai (United States), Daiichi Sankyo (United States), Astellas Pharma (United States), Celgene (United States), Merck Healthcare KGaA, Darmstadt (Germany), GlaxoSmithKline Research & Development Limited (United Kingdom), Janssen Research & Development (United States), Vertex Pharmaceuticals (United States), Technical University of Munich, Bayer (Germany), Incyte (United States)
ORCID: 0000-0002-2968-638X
Observed ORCID: 0000-0002-2968-638X
OpenAlex ID: A5036106892
Predicting drug metabolism: experiment and/or computation?
2015 · Johannes Kirchmair, Andreas H. Göller, et al. · Nature Reviews Drug Discovery · 523
PDF
Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans
2009 · C. Weinz, T. Schwarz, et al. · Drug Metabolism and Disposition · 384
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure
2017 · Markus Follmann, Jens Ackerstaff, et al. · Journal of Medicinal Chemistry · 216
Discovery of Riociguat (BAY 63‐2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension
2009 · Joachim Mittendorf, Stefan Weigand, et al. · ChemMedChem · 188
Immunoquantitation of FMO1 in Human Liver, Kidney, and Intestine
2000 · Catherine K. Yeung, Dieter H. Lang, et al. · Drug Metabolism and Disposition · 130
In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans
2009 · D. Lang, C. Freudenberger, et al. · Drug Metabolism and Disposition · 114
Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions—an Industry Perspective
2016 · Tonika Bohnert, Aarti Patel, et al. · Drug Metabolism and Disposition · 111
Identification of Enzymes Involved in the Metabolism of Atrazine, Terbuthylazine, Ametryne, and Terbutryne in Human Liver Microsomes
1997 · Dieter H. Lang, Allan E. Rettie, et al. · Chemical Research in Toxicology · 82
Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro
2018 · Michael Gerisch, Roland Heinig, et al. · Drug Metabolism and Disposition · 74
PDF
In vitro evaluation of potential in vivo probes for human flavin‐containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms
2000 · Dieter H. Lang, Allan E. Rettie · British Journal of Clinical Pharmacology · 73
PDF
In vitro metabolism of atrazine, terbuthylazine, ametryne, and terbutryne in rats, pigs, and humans.
1996 · D Lang, D Criegee, et al. · Drug Metabolism and Disposition · 72
Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)
2021 · Michael G. Hahn, Thomas Lampe, et al. · Journal of Medicinal Chemistry · 69
A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monooxygenases in human liver microsomes
1996 · A. Grothusen, J. Hardt, et al. · Archives of Toxicology · 69
Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85‐8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases
2015 · Franz von Nussbaum, Volkhart M.‐J. Li, et al. · ChemMedChem · 66
PDF
Highly Variable Expression of CYP1A1 in Human Liver and Impact on Pharmacokinetics of Riociguat and Granisetron in Humans
2019 · Dieter Lang, Martin Radtke, et al. · Chemical Research in Toxicology · 60
Sorafenib Hepatobiliary Disposition: Mechanisms of Hepatic Uptake and Disposition of Generated Metabolites
2013 · Brandon Swift, Noelia Nebot, et al. · Drug Metabolism and Disposition · 59
Unraveling the differential impact of PAHs and dioxin-like compounds on AKR1C3 reveals the EGFR extracellular domain as a critical determinant of the AHR response
2021 · Christian Vogeley, Natalie C. Sondermann, et al. · Environment International · 55
PDF
Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.
2001 · A Yu, H Dong, et al. · PubMed · 55
Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects
2017 · Michael Gerisch, Frank-Thorsten Hafner, et al. · Cancer Chemotherapy and Pharmacology · 47
PDF
Cytochrome P450-dependent desaturation of lauric acid: isoform selectivity and mechanism of formation of 11-dodecenoic acid
1998 · Xiangming Guan, Michael B Fisher, et al. · Chemico-Biological Interactions · 47
Stable Expression of Human Cytochrome P450 3A4 in Conjunction with Human NADPH-Cytochrome P450 Oxidoreductase in V79 Chinese Hamster Cells
1996 · Anneliese Schneider, Wolfgang A. Schmalix, et al. · Archives of Biochemistry and Biophysics · 46
Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity
1995 · D. Lang, R. Böcker · Journal of Chromatography B Biomedical Sciences and Applications · 46
Potent and Selective Human Neutrophil Elastase Inhibitors with Novel Equatorial Ring Topology: in vivo Efficacy of the Polar Pyrimidopyridazine BAY‐8040 in a Pulmonary Arterial Hypertension Rat Model
2015 · Franz von Nussbaum, Volkhart M. Li, et al. · ChemMedChem · 43
Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders
2023 · Susanne Roehrig, Jens Ackerstaff, et al. · Journal of Medicinal Chemistry · 41
Design and Synthesis of Potent and Selective Azaindole‐Based Rho Kinase (ROCK) Inhibitors
2008 · Hartmut Schirok, Raimund Kast, et al. · ChemMedChem · 41
Works count: 57
Citation count: 2,969
H-index: 27
I10-index: 37
Year
Topic
Type